A61P 13/12
Drugs for disorders of the urinary system: of the kidneys
Official title: of the kidneys
A61P13/12 (Drugs for disorders of the urinary system: of the kidneys) appears on 16,097 US grants and 25,441 published applications in this corpus.
Search patents in A61P- Granted patents
- 16,097
- Published applications
- 25,441
- Assignees
- 5,426
- Inventors
- 35,421
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 4 | 0 |
| 1992 | 4 | 0 |
| 1993 | 9 | 0 |
| 1994 | 5 | 0 |
| 1995 | 11 | 0 |
| 1996 | 26 | 0 |
| 1997 | 33 | 0 |
| 1998 | 78 | 0 |
| 1999 | 92 | 0 |
| 2000 | 124 | 0 |
| 2001 | 199 | 60 |
| 2002 | 294 | 406 |
| 2003 | 310 | 733 |
| 2004 | 265 | 965 |
| 2005 | 277 | 978 |
| 2006 | 400 | 1031 |
| 2007 | 438 | 1093 |
| 2008 | 489 | 1286 |
| 2009 | 604 | 1496 |
| 2010 | 848 | 1795 |
| 2011 | 874 | 1526 |
| 2012 | 1040 | 1508 |
| 2013 | 1181 | 1298 |
| 2014 | 1150 | 1350 |
| 2015 | 1035 | 1243 |
| 2016 | 892 | 1230 |
| 2017 | 946 | 1200 |
| 2018 | 810 | 1063 |
| 2019 | 790 | 1006 |
| 2020 | 656 | 838 |
| 2021 | 607 | 717 |
| 2022 | 436 | 690 |
| 2023 | 347 | 571 |
| 2024 | 338 | 546 |
| 2025 | 311 | 516 |
| 2026 | 172 | 296 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Manufacture, formulation and dosing of apraglutide29 Sep 2026US 12,746,276 B2VectivBio AG
- Method for manufacturing mitochondria-rich plasma22 Sep 2026US 12,741,068 B2Taiwan Mitochondrion Applied Technology Co., Ltd.
- Medicament containing enteropeptidase inhibitor as active ingredient, and method for preventing and or treating polycystic kidney disease containing administering the same8 Oct 2026US 2026/0306441 A1National University Corporation Hokkaido University
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Sik inhibitors to treat chronic kidney disease8 Oct 2026US 2026/0306463 A1The General Hospital Corporation
- Functional protective agent for organ or tissue8 Oct 2026US 2026/0306488 A1Jellice Co., Ltd.
- Methods and pharmaceutical compositions comprising d1-like dopamine receptor agonist for the treatment of autosomal dominant polycystic kidney disease8 Oct 2026US 2026/0306504 A1Centre Hospitalier Universitaire De Rouen
Most cited
By later US patents
- Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity604US 6,602,684 B1GlycArt Biotechnology AG · 2003
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009
- Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents332US 6,603,008 B1Pfizer Inc. · 2003
- Human antibodies that bind human TNFα308US 6,258,562 B1BASF SE · 2001